Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.

Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.

Item
http://www.wikidata.org/entity/Q55032245
Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.HER2 gene copy number and breast cancer-specific survival.Breast cancer in Angola, molecular subtypes: a first glanceThe impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancerImpact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category.Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?Characterization of HER2 gene amplification heterogeneity in invasive and in situ breast cancer using bright-field in situ hybridization.Relationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
P2860

Application of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatment.

Item
http://www.wikidata.org/entity/Q55032245
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Application of the 2013 ASCO/C ...... ients for anti-HER2 treatment.
@en
Application of the 2013 ASCO/C ...... ients for anti-HER2 treatment.
@nl
type
label
Application of the 2013 ASCO/C ...... ients for anti-HER2 treatment.
@en
Application of the 2013 ASCO/C ...... ients for anti-HER2 treatment.
@nl
prefLabel
Application of the 2013 ASCO/C ...... ients for anti-HER2 treatment.
@en
Application of the 2013 ASCO/C ...... ients for anti-HER2 treatment.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698
P356
P1433
P1476
Application of the 2013 ASCO/C ...... tients for anti-HER2 treatment
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P50
P577
P6179
P698